HWAY

Something New!

by

Hi everyone: To stay true to our mission, you’ll find something new regarding our methodology. In the coming weeks, you’ll see this table in our work going forward. We just wanted to let you know. We appreciate your membership very much!   ——————————————— About Our Name But how, you will ask, does one decide what [stocks are] “attractive”? Most analysts feel they must choose between two approaches customarily thought to be in opposition: “value” and “growth,”…We view that as fuzzy thinking…Growth is always a component of value [and] the very term “value investing” is redundant.                          — Warren Buffett, Berkshire Hathaway annual report, 1992 At Valuentum, we take Buffett’s thoughts one step further. We think the best opportunities arise from an understanding of … Read more

New Payment Option! Valuentum Research Update!

by

Hi everyone: — We’re excited to say that we’re adding additional payment flexibility at Valuentum. — Many members have expressed interest in paying via other providers, and we have added Square to the mix. You can use credit or debit card or bank (ACH) to pay via invoice. — With all of the goings-on in the financial technology and payments space, we wanted to continue to provide members options to pay their memberships how they want and through who they want. You can always reach out to us at info@valuentum.com. — You’ll notice that we’ve also tightened our focus at Valuentum during the past 12-24 months in advance of what has certainly become a more difficult 2022 than even some … Read more

Our Reports on Stocks in the Health Care Providers & Services Industry

by

Structure of the Healthcare Providers & Services Industry Firms in the healthcare providers/services industry provide a range of services: help pharma/biotech companies develop prescription medicines; perform various diagnostic testing services to patients, physicians, payors, and employers; and offer healthcare information technology solutions to hospitals and other organizations, which is supported by the sector’s focus on cost containment and improving outcomes. Drug development entities benefit from outsourcing of R&D by pharma/biotech firms, diagnostic testing companies benefit from the growing/aging population and the increasing need for clinical testing, which is an essential service. US healthcare reform will present both opportunities and challenges. We’re neutral on the group. We have dropped coverage of the Healthcare Providers & Services Industry.